Central but not peripheral glucoprivation is impaired in monosodium glutamate-treated rats.
In the present study, newborn male Wistar rats were injected, subcutaneously, five times, every other day, with monosodium glutamate (MSG, 4 g/kg bw) or saline (as control, C), during the neonatal period. MSG animals developed destruction of the arcuate nuclei (ARC) with absence of NPY-immunoreactive cell bodies, which impaired both the food intake (baseline) and the 2-deoxy-D-glucose (2DG) glucoprivic feeding response. Increases in the immunoreactivity of corticotropin-releasing hormone-cell bodies in the paraventricular nuclei might have developed to compensate for the atrophy of the pituitary in MSG-treated rats. After systemic 2DG injection, neither the C nor the MSG rats increased their food intake, but they showed similar hyperglycemic responses, whereas plasma free fatty acids (FFA) increased only in the C group. In other groups, 2DG, norepinephrine (NE), neostigmine (NEO) and saline were intracerebroventricularly (i.c.v.) administered. In this condition, impairment of the hyperglycemic and food intake responses, associated to a lower increase in plasma FFA levels, were observed. As opposed to this, the MSG treatment gives support to NE effects, enhancing food intake, as well as plasma glucose and FFA levels. After NEO, plasma glucose increased only in the MSG group, while plasma FFA levels were elevated in the C rats. Taken together, the results obtained after MSG treatment point to a separate neural control of the hyperglycemic response and of the lipid mobilization when stimulated by central 2DG, NE or NEO administration. It seems likely that the excitatory neural pathway that controls lipid metabolism and is present in C rats was destroyed by the MSG treatment.
de Andrade
Iracema Senna
IS
Department of Physiology, Division of Neurophysiology and Endocrine Physiology, Universidade Federal de São Paulo, Escola Paulista de Medicina, São Paulo, SP 04023-060, Brazil.
Gonzalez
João Carlos Gonzalez
JC
Hirata
Aparecida Emiko
AE
Carneiro
Glaucia
G
Amado
Débora
D
Cavalheiro
Esper Abrão
EA
Dolnikoff
Miriam Sterman
MS
D000818:Animals; D000831:Animals, Newborn; D001111:Arcuate Nucleus of Hypothalamus / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D001786:Blood Glucose / Q000032:analysis; D003346:Corticotropin-Releasing Hormone / Q000378:metabolism; D003847:Deoxyglucose / Q000008:administration & dosage / Q000494:pharmacology; D004435:Eating / Q000187:drug effects; D005230:Fatty Acids, Nonesterified / Q000097:blood; D005947:Glucose / Q000172:deficiency*; D006943:Hyperglycemia / Q000503:physiopathology; D007275:Injections, Intravenous; D007276:Injections, Intraventricular; D008297:Male; D009388:Neostigmine / Q000008:administration & dosage / Q000494:pharmacology; D009478:Neuropeptide Y / Q000378:metabolism; D009638:Norepinephrine / Q000008:administration & dosage / Q000494:pharmacology; D010286:Paraventricular Hypothalamic Nucleus / Q000187:drug effects / Q000378:metabolism; D051381:Rats; D017208:Rats, Wistar; D012970:Sodium Glutamate / Q000008:administration & dosage / Q000494:pharmacology*
D001786:Blood Glucose; D005230:Fatty Acids, Nonesterified; D009478:Neuropeptide Y; D009388:Neostigmine; D003346:Corticotropin-Releasing Hormone; D003847:Deoxyglucose; D005947:Glucose; D012970:Sodium Glutamate; D009638:Norepinephrine